Diagnostic methods for cancer patients

By determining the appropriate radioactive concentration and administration route in the salt form of copper-64, the problem of unclear diagnostic dosage regimen of copper-64 in the prior art has been solved, the accuracy and safety of treatment have been achieved, and the treatment has been improved. Effectiveness and patient compliance.

CN119095629APending Publication Date: 2024-12-06S·瓦伦蒂尼
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380024433.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-03
Filing Date
2023-03-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, when using copper-64 (64Cu) as a therapeutic diagnostic agent, there is a lack of a clear dosage regimen and method, which cannot effectively predict the therapeutic effect, and the biodistribution of the tracer cannot be accurately obtained, making the treatment difficult to proceed accurately.

Method used

Using copper-64 in salt form (such as 64CuCl2) as a dual-action diagnostic and therapeutic agent, the radioactive concentration of copper-64 is determined from 50 to 3,500MBq/mL by evaluating subjects’ PET/CT or PET/MRI imaging. Between, it is used to select a subject suitable for treatment and administered by intravenous injection or other routes to achieve treatment.

Benefits of technology

It realizes the safe and effective delivery of 64CuCl2 therapeutic dose, improves the accuracy and effectiveness of treatment, reduces the risk of adverse reactions, can monitor treatment responses in real time, and improves patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005017641520000031
    Figure BDA0005017641520000031
  • Figure BDA0005017641520000041
    Figure BDA0005017641520000041
  • Figure HDA0005017641530000011
    Figure HDA0005017641530000011
Patent Text Reader

Abstract

Described herein are radiopharmaceutical compositions comprising copper-64 (64Cu + +) in ionic form as an active ingredient, and suitable excipients and / or diluents, having a radioactivity concentration at a calibrated time of between 50 and 3,500 MBq / mL. Such radiopharmaceutical compositions are useful in methods of treating subjects with neoplasms. Such methods may include the step of assessing whether the patient is suitable for treatment, wherein 64Cu + + cellular uptake is detected. If ingestion is not detected, treatment is not suggested. If radioactive copper uptake from a cancer lesion can be detected, this has a predicted value of response to the treatment, and the subject is selected for treatment. If the patient is suitable for treatment and is selected for treatment, the method further comprises the step of treating cancer in the subject by administering a therapeutically effective amount of the same 64Cu + + salt.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a radiopharmaceutical composition comprising as an active ingredient copper-64( 64 Cu ++ ), and suitable excipients and / or diluents, having a radioactivity concentration of between 50 and 3,500 MBq / mL when calibrated, optionally at, below or above 925 MBq / mL when calibrated. Such radiopharmaceutical compositions can be used in methods of treating subjects affected by neoplasms. Background Art

[0002] Copper is an essential trace element with multiple physiological functions. It plays an important role in tumor angiogenesis and can stimulate endothelial cell proliferation (Hu, 1998). Under physiological conditions, copper metabolism is strictly regulated by complex homeostatic mechanisms. In tumor diseases, copper metabolism and its cellular deposition are also significantly altered - from the cytoplasm of normal tissues to the nuclear and perinuclear regions of tumors (Fuchs et al., 1989). In the past two decades, many preclinical studies have shown that copper has an effect on cancer development; in particular, changes in copper have been observed in mice and rats with tumors. In addition, serum copper levels and ceruloplasmin levels are significantly increased in patients with various types of tumors compared with healthy subjects (Fisher and Shifrine, 1978, Scanni et al., 1979). In particular, some authors have reported increased copper levels in the serum of patients with different types of tumors, such as lung cancer (Bai et al., 2019), cervical cancer (Zhang et al., 2018), and prostate cancer (Saleh et al., 2019). Furthermore, serum copper and ceruloplasmin values ​​in glioma patients showed significantly higher concentrations compared with healthy subjects or subjects affected by non-neoplastic neurological diseases ( Manjula et al., 1992 ).

[0003] Currently, the importance of copper in carcinogenesis and metastasis formation, as well as resistance to treatment, has been explored. In addition, research work on copper dysregulation in oncology and the recent understanding of copper metabolism have led to the development of multiple therapeutic strategies targeting this trace element. Despite the intensive research and improved knowledge of copper metabolism over the years, some shadow areas still exist (Lelièvre et al., 2020).

[0004] Since the radioactive isotope copper-64 ( 64Cu), it is possible to observe dysregulated levels of copper in tumor patients. This is one of the copper isotopes that shows potential in the field of nuclear medicine and can be used for PET (positron emission tomography) imaging, which can be PET / CT (computed tomography) or PET / MRI (magnetic resonance imaging). Once injected into the patient, this isotope tracks the abnormal distribution of copper in the body and can be visualized by PET. Copper-64 is the only copper isotope with three decay modes, and its half-life (12.7 hours) allows for efficient clinical imaging at delayed scan times, taking advantage of better target to background signal; in addition, it allows for convenient distribution of radiopharmaceuticals after synthesis at centralized production sites, and easier management of scheduled activities in clinical nuclear medicine facilities.

[0005] 64 Cu can undergo β+ emission to nickel-64 and β- emission to zinc-64. Both daughter nuclides are stable. In addition to β-, 64Cu also decays by emission of Auger electrons, which have an average energy of 2keV and a range of 126nm in tissue (Howell, 1992), and are considered high LET (linear energy transfer) radiation. The ability to reach the nucleus and emit Auger electrons near DNA can lead to tumor cell death, and this mechanism may enhance cancer treatment.

[0006] The β+ emission makes it useful as a diagnostic agent, and indeed, different literature evidence suggests that copper chloride ( 64 CuCl 2 ) form of 64Cu is able to be a good diagnostic imaging agent for different cancer types such as breast cancer, prostate cancer or melanoma, both in preclinical studies (Peng et al., 2006; Cai et al., 2014, Qin et al., 2014) and in clinical settings. In prostate cancer patients, 64 CuCl 2 PET / CT appears to show better results than clinical standards 18 F-FCH has superior properties (Capasso et al., 2015; Piccardo et al., 2017) and has been shown to be effective in glioblastoma patients. 64 CuCl 2 It also shows potential as a diagnostic agent (Panichelli et al., 2016). In contrast, as mentioned above, Auger electron emission has potential therapeutic uses, but the evidence in the literature is still less.

[0007] The last few years have seen unprecedented progress in the field of nuclear medicine: one of the main drivers is the so-called “theranostic” concept, which combines the use of diagnostic biomarkers with treatment selection. Recent developments have significantly broadened the scope of radionuclide imaging and therapy, which now extends to neuroendocrine tumors, prostate cancer or hematological malignancies (Lapa et al., 2019).

[0008] The key point in the application of theranostic agents is that the systemically administered dose should reach the target tissue in sufficient quantities. Ideally, theranostic compounds involve chemically and biologically identical compounds. In fact, the market offers so-called "theranostic pairs", i.e. combinations of diagnostic and therapeutic agents (Table 1). Most of them are not chemically or biologically identical, but they are similar in biodistribution and the first injection of the diagnostic agent can predict the biodistribution of the therapeutic counterpart. Diagnostic Radiometals 111 In and 68 Ga and its therapeutic counterparts 90 Y and 177 Lu are all trivalent metals and can be attached to targeting moieties using the same chelators, but there are differences in their chemical structures, which can affect their biological properties and biodistribution (Ballinger et al., 2018).

[0009] Table 1. Theranostic agents / pairs currently in clinical use (Ballinger et al., 2018)

[0010] Clinical indications Diagnostic agents Therapeutic agents Hyperthyroidism or thyroid cancer <![CDATA[1 23 I-Iodide]]> <![CDATA[ 131 I-Iodide]]> Adrenergic tumors <![CDATA[ 123 I-Iodophenylguanidine]]> <![CDATA[ 131 I-Iodophenylguanidine]]> Prostate cancer bone metastasis <![CDATA[ 99m Tc-MDP]]> <![CDATA[ 223 Ra Chloride]]> Non-Hodgkin's lymphoma <![CDATA[ 111 In-Ibrutinib]]> <![CDATA[ 90 Y-Ibrutinib]]> Neuroendocrine tumors <![CDATA[ 68 Ga-DOTATATE]]> <![CDATA[ 68 Lu-GIFTED]]> Prostate cancer <![CDATA[ 68 Ga-PSMA-11]]> <![CDATA[ 177 Lu-PSMA-617]]>

[0011] However, dosing regimens and their use in theranostic approaches remain unclear to experts in the field and cannot be simply extrapolated due to the lack of clinical data for this therapeutic approach. Table 2 reports different studies showing that 64 CuCl 2 It has potential therapeutic uses in different cancers (e.g., prostate cancer, glioblastoma, melanoma), but no study has predicted appropriate theranostic dosing regimens and methods.

[0012] Table 2. 64 CuCl 2 A summary of the study with particular attention to its main theme, research topic, radiotracer used and main results

[0013]

[0014]

[0015] All of these studies involve 64 CuCl 2There are no preclinical (animal or in vitro) applications of Cu-64, and none of these studies reported clinical data. In addition, the literature data are vague and do not clearly define diagnostic methods using Cu-64, its optimal formulation, optimal radioactivity concentration, its dosing regimen, and dosing intervals that can be used safely and effectively.

[0016] Ferrari et al. studied the nude mice implanted with tumors. 64 CuCl 2 Treatment was performed by simulating single-dose and multiple-dose treatment regimens (333MBq / day and 55.5MBq / day x 6 days, respectively), and the results were analyzed to evaluate the efficacy of the treatment. The experiments were performed in animals with 3-week-old tumors. In this study, three groups of mice were compared: 30 animals that did not receive treatment, 30 animals that received 333MBq, and 55.5MBq. 64 CuCl 2 Animals that received a single dose and 30 animals that received 55.5 MBq for 6 days 64 CuCl 2 Animals treated with the multiple-dose regimen were injected once daily.

[0017] In addition, Qin et al. showed the therapeutic ability of copper chloride against melanoma. Specifically, once the tumor reached 0.5–0.8 cm in diameter, tumor-bearing mice were injected with a dose of 64 CuCl 2 (about 74MBq), and the tumor size was monitored during treatment. 64 CuCl 2 Under treatment, tumor growth in the B16F10 and A375M models was much slower than in the control group. The survival rate of the treatment group was significantly improved compared with the control group.

[0018] Given these preclinical data, it is not possible to relate these doses to humans.

[0019] EP3071241B1 discloses a formulation and average dosage, but only provides general indications without evidence of safety and efficacy of the dosage, nor does it explain the therapeutic diagnosis method and its use as a therapeutic diagnostic tracer.

[0020] use 64 CuCl 2 Therapeutic and diagnostic methods have not yet been elucidated. Despite many therapeutic advances, many common cancers, such as breast cancer, prostate cancer, and brain cancer, remain common causes of death and new treatments are needed. In addition, common treatments such as radiotherapy and chemotherapy are actually showing resistance to treatment. Therefore, the development of new and effective treatments is essential for cancer patients.

[0021] Furthermore, commercially available diagnostics use different molecules for diagnosis and treatment, which carries the risk of not being able to accurately obtain tracer biodistribution, predict treatment efficacy, and monitor treatment response at the same therapeutic dose.

[0022] In view of the shortcomings of the existing technology, an effective diagnostic method is provided for adult and pediatric tumor patients to administer 64 CuCl 2 , will be very beneficial.

[0023] The present invention solves the problem of safe and effective transportation 64 CuCl 2 The question of therapeutic dosage. Summary of the invention

[0024] The present invention is based on the discovery that, unlike what has been reported to date, copper-64 in salt form (e.g. 64 CuCl 2 ) can be used as a true diagnostic agent, not just a component of a diagnostic pair. In other words, the same chemical entity (copper) and the same isotope (64) can be used for both patient selection and treatment. The exact same product has a dual role, and the first injection can accurately predict the biodistribution of subsequent injections. The first step involves using the composition to evaluate whether the subject affected by the neoplasm is suitable for receiving a specific therapy or treatment, which is also referred to herein as the "selection step", meaning that this step allows the selection of subjects who can receive the subsequent specific therapy or treatment. If the subject results meet the treatment conditions and is selected for treatment, the subject is treated by administering a therapeutically effective amount of a radiopharmaceutical composition, wherein the radiopharmaceutical composition contains copper-64 ( in ionic form as an active ingredient) 64 Cu ++ ), in combination with suitable excipients and / or diluents, the radioactivity concentration at calibration is between 50 and 3,500 MBq / mL. In particular, the present invention relates to a radiopharmaceutical composition comprising copper-64 ( 64 Cu ++ ), in combination with suitable excipients and / or diluents, the radioactivity concentration at the time of calibration is between 50 and 3,500 MBq / mL, optionally at, below or above 925 MBq / mL at the time of calibration.

[0025] Another object of the present invention is a radiopharmaceutical composition comprising as active ingredient copper-64 ( 64 Cu ++), in combination with suitable excipients and / or diluents, having a radioactivity concentration when calibrated between 50 and 3,500 MBq / mL, optionally equal to, below or above 925 MBq / mL when calibrated, for use as a drug.

[0026] Another object of the invention is a method for treating neoplasms, comprising administering a radiopharmaceutical composition comprising as active ingredient copper-64 ( 64 Cu ++ ), in combination with suitable excipients and / or diluents, having a radioactivity concentration at calibration between 50 and 3,500 MBq / mL, optionally at calibration equal to, below or above 925 MBq / mL.

[0027] Another object of the present invention is to contain copper-64 ( 64 Cu ++ ) having a radioactive concentration between 50 and 3,500 MBq / mL when calibrated, optionally equal to, lower than or higher than 925 MBq / mL when calibrated, for the preparation of a medicament.

[0028] In order to evaluate the preferred compositions for clinical trials with diagnostic methods, different in vitro tests were performed from both pharmaceutical and biological point of view.

[0029] The inventor showed 64 CuCl 2 The ability to produce cytotoxic effects on tumor cells in different tumor lines. This ability was improved at radioactivity concentrations above 925MBq / mL compared to lower concentrations. This is the first time that the effect of drug radioactivity concentration has been correlated with cytotoxic effects for translation to humans.

[0030] The inventors conducted internalization and survival studies on different cancer cell lines (U87MG [glioblastoma], PC-3 [prostate cancer], CAMA1 [breast cancer], C8161 [melanoma], HT-29 [colorectal cancer]), A549 [lung cancer], using the same amount (dose) of radioactivity (e.g., 10 MBq), but at different radioactivity concentrations, e.g., 2,775 MBq / mL versus 1,850 MBq / mL versus 925 MBq / mL.

[0031] The results showed that in all cell lines, the radioactivity concentration had a direct effect on cellular uptake 4 h after treatment: uptake was significantly increased at higher concentrations compared to the lowest concentration ( Figure 1 ). The increased uptake at a concentration of 2,775 MBq / mL also resulted in an increased cell killing effect 24 hours after treatment, as shown, for example, in the cell survival curve of the U87MG line ( Figure 2 ). This effect of radioactivity concentration could have a significant impact on the patient and thus optimize treatment. 64 The mechanism of Cu reaching tumor cells, different radioactivity concentrations, i.e. "number of nuclear divisions per unit time in a given amount of preparation", affect the biodistribution in vivo. Without wishing to be bound by any theory, in fact, the greater the number of nuclear divisions of the isotope, the less stable the connection between the cation and the circulating proteins responsible for transporting copper to the target organs. The less stable connection to the carrier protein makes the isotope more accessible to tumor cells, which is associated with a higher genotoxic effect.

[0032] Generally speaking, for radiopharmaceuticals, the radioactivity concentration affects the radiochemical purity, and a decrease in radioactivity concentration increases the radiochemical purity. Therefore, for technicians, increasing 64 The benefit of the radioactivity concentration of Cu radiopharmaceuticals that can bring about biological effects is not obvious: in theory, an increase in radioactivity concentration usually leads to an increase in impurity content, including "non-radioactive" copper. However, contrary to one's expectations, in the present invention, the formulation with a higher radioactivity concentration has a high purity: a low content of "non-radioactive" copper and a high content of "radioactive" copper-64 ions, which can release a higher content of Auger electrons in tumor cells. Compared with other formulations (925MBq / mL), this can improve the therapeutic effect.

[0033] Considering our in vitro experiments, the calibration 64 CuCl 2 2,775MBq / mL was chosen as the preferred radioactivity concentration to be injected into the patient, as it is the most suitable for diagnostic methods, showing advantages both in terms of efficacy and practicality. In fact, this high radioactivity concentration solves the problem of having a large amount of radioactivity required for treatment in a small volume, since low radioactivity concentration values ​​correspond to high volumes, while high radioactivity concentration values ​​correspond to small values. The reduction in volume represents an advantage in terms of radiological protection, and in fact, the nurse can directly inject the patient, reducing the exposure time compared to each continuous infusion administration, and improving patient compliance.

[0034] However, further clinical evidence (also reported in the Examples section) suggests that even lower radioactivity concentrations (equal to or below 925 MBq / mL) are effective in treating neoplasms if the route of administration is intravenous infusion and the volume of the radiopharmaceutical composition to be administered is adjusted according to the dose to be administered to the subject.

[0035] Use lower or higher concentrations of 64 CuCl 2 The PET / CT imaging evaluation obtained showed uptake by neoplastic cells, which led the inventors to understand that 64CuCl 2 Able to enter neoplastic cells, it can therefore induce a therapeutic effect independent of the route of administration.

[0036] Considering that in subjects affected by neoplasms, copper homeostasis is different and copper transporters are dysregulated, 64 Cu follows this abnormal metabolic pathway and reaches the tumor lesion. 64 The route of Cu introduction into the human body is irrelevant.

[0037] The radiopharmaceutical composition of the present invention can be administered to a subject by any route of administration, including enteral, parenteral, inhalation, oral, and transdermal. The route of administration is preferably parenteral, including intravenous, intramuscular, intradermal, subcutaneous, intratumoral, intracavitary, and intrathecal. More preferably, the route of administration is intravenous injection, infusion, or implantation.

[0038] According to a specific embodiment of the present invention, the administration route of the radiopharmaceutical composition of the present invention is injection.

[0039] According to another specific embodiment of the present invention, the administration route of the radiopharmaceutical composition of the present invention is infusion.

[0040] According to another specific embodiment of the present invention, the administration route of the radiopharmaceutical composition of the present invention is intratumorally.

[0041] According to another specific embodiment of the present invention, the administration route of the radiopharmaceutical composition of the present invention is intracavitary.

[0042] According to another specific embodiment of the present invention, the administration route of the radiopharmaceutical composition of the present invention is intrathecal.

[0043] The radiopharmaceutical compositions of the present invention may also be administered to a subject using any medical device.

[0044] According to a specific embodiment of the present invention, preferably when the administration route is intravenous injection, the radioactivity concentration of the radiopharmaceutical composition of the present invention is between 930 MBq / mL and 3,500 MBq / mL during calibration.

[0045] According to a specific embodiment of the present invention, preferably when the administration route is intravenous injection, the radioactivity concentration of the radiopharmaceutical composition of the present invention is between 1,000 MBq / mL and 2,800 MBq / mL during calibration.

[0046] According to a specific embodiment of the present invention, preferably when the administration route is intravenous injection, the radioactivity concentration of the radiopharmaceutical composition of the present invention is 1,850 MBq / mL.

[0047] According to a specific embodiment of the present invention, preferably when the administration route is intravenous injection, the radioactive concentration of the radiopharmaceutical composition of the present invention during calibration is 2,775 MBq / mL.

[0048] According to one embodiment, the pharmaceutical composition is a solution for injection, which can be diluted with 0.9% NaCl before injection.

[0049] According to other specific embodiments of the present invention, preferably, when the administration route is intravenous infusion, the radioactivity concentration of the radiopharmaceutical composition of the present invention during calibration is between 50 MBq / mL and 925 MBq / mL.

[0050] According to other specific embodiments of the present invention, preferably, when the administration route is intravenous infusion, the radioactivity concentration of the radiopharmaceutical composition of the present invention during calibration is between 80 MBq / mL and 750 MBq / mL.

[0051] According to a further specific embodiment of the present invention, preferably, when the administration route is intravenous infusion, the radioactivity concentration of the radiopharmaceutical composition of the present invention during calibration is between 100 MBq / mL and 600 MBq / mL.

[0052] According to a further specific embodiment of the present invention, preferably, when the administration route is intravenous infusion, the radioactivity concentration of the radiopharmaceutical composition of the present invention at the time of calibration is between 200MBq / mL and 450MBq / mL, optionally at 277MBq / mL at the time of calibration, optionally at 350MBq / mL at the time of calibration.

[0053] According to a further specific embodiment of the present invention, preferably, when the administration route is intravenous infusion, the radioactivity concentration of the radiopharmaceutical composition of the present invention is equal to 925 MBq / mL when calibrated.

[0054] According to another specific embodiment of the present invention, preferably, when the administration route is intravenous injection, the radioactivity concentration of the radiopharmaceutical composition of the present invention is equal to 1,850 MBq / mL during calibration.

[0055] According to another specific embodiment of the present invention, preferably, when the administration route is intravenous injection, the radioactivity concentration of the radiopharmaceutical composition of the present invention is equal to 2,775 MBq / mL during calibration.

[0056] Counterions, such as chloride ions, acetate ions, citrate ions, etc., may be present in the radiopharmaceutical composition of the present invention to prepare a solution with a pH suitable for injection.

[0057] For example, the formulation may consist of 5% 64 CuCl2 , 2% acetate buffer solution, 10-93% 0.9% NaCl solution, or for example the formulation may consist of 8% 64 Cu(OAc) 2 , 4% acetate buffer solution, 12-88% water for injection (WFI), and 1% antioxidant (such as ascorbic acid).

[0058] According to another embodiment of the present invention, the specific activity of the radiopharmaceutical composition is 5.10 2 Until May 10 4 MBq 64 Cu / μg copper.

[0059] According to another embodiment of the present invention, the specific activity of the radiopharmaceutical composition is between 1,000 and 10,000 MBq. 64 Cu / μg copper, optionally 5,000 MBq 64 Cu / μg copper.

[0060] The radiopharmaceutical composition is preferably a sterile solution that can be used as a ready-to-use solution for intravenous injection.

[0061] The radiopharmaceutical composition preferably has a pH suitable for direct injection, with a pH between 4-8.

[0062] Another embodiment of the present invention relates to the radiopharmaceutical composition of the present invention as previously described, for use in the treatment of neoplasms.

[0063] According to one embodiment of the present invention, treatment of neoplasms may employ a diagnostic method, thus comprising a first step of assessing whether a subject is suitable for treatment, a next step of treating the selected subject, and optionally, a next step of monitoring the subject's response to treatment.

[0064] In other words, the diagnostic method is a method of treating a neoplasm in a human subject comprising the steps of:

[0065] a) administering an effective amount of a radiopharmaceutical composition comprising as an active ingredient copper-64 ( 64 Cu ++ ), combined with suitable excipients and / or diluents, to assess whether the subject is suitable for subsequent treatment;

[0066] b) acquiring images of the subject by PET / MRI or PET / CT to demonstrate any uptake of copper-64 by neoplastic cells of the cancerous lesion;

[0067] c) if there is evidence of copper-64 uptake by the neoplastic cells, subjecting the subject to a treatment cycle comprising administering to the subject a therapeutically effective amount of a radiopharmaceutical composition comprising, as an active ingredient, copper-64 in ionic form ( 64 Cu ++ ), combined with suitable excipients and / or diluents.

[0068] The purpose of steps (a) and (b) in the above method is to evaluate the lesions identified by PET / CT or PET / MRI imaging of the subject. 64 CuCl 2 The uptake of copper-64 in the tumor lesions can be used to select subjects for treatment. If the imaging assessment shows copper-64 uptake, the subject can be enrolled in treatment, otherwise, if there is no uptake, no treatment is recommended. If there is copper uptake in the tumor lesions, this can also have predictive value for treatment response.

[0069] According to step a), the patient first receives a 64 CuCl 2 Administration, a single dose is between 3MBq / kg and 14MBq / kg, preferably between 5.3MBq / kg and 13MBq / kg. For example, a patient weighing 70 kg may receive 371MBq 4 CuCl 2 The dose is usually given intravenously. For a child weighing 25 kg, the diagnostic dose is 132.5 MBq, and the dose is preferably in the range of 130-200 MBq.

[0070] According to step b), in order to obtain an image of the patient's body, preferably 64 CuCl 2 Perform PET / CT or PET / MRI imaging 1 to 4 hours after injection and evaluate PET imaging to confirm that the patient's cancer lesions 64 CuCl 2 Post-drug PET imaging analysis considered lesions positive and determined the target-to-background ratio (TBR).

[0071] According to one specific embodiment of the present invention, the TBR value of a lesion of a human subject having a neoplasm is measured to demonstrate the uptake of copper-64 in the subject's lesion.

[0072] TBR is a value obtained by objective evaluation using methods that include computer output and does not require physician interpretation. Specifically, TBR is the maximum SUV (SUV max) to the maximum SUV (Standardized Uptake Value) of some normal tissue level considered as “background tissue” (BKG). The SUV of each acquisition site corresponding to the lesion must be measured by locating a VOI (Volume of Interest) that completely includes the acquisition site. max .

[0073] TBR will be calculated as follows:

[0074] For lymphadenopathy: SUV max (lesion) / SUV max (Mediastinum)

[0075] For bone lesions: SUV max (lesion) / SUV max (muscle)

[0076] For visceral lesions: SUV max (lesion) / SUV max (contralateral organ or mediastinum)

[0077] The SUV measured on the VOI drawn on each side of the gluteus will be calculated max The arithmetic mean of the values ​​was calculated and referred to as the muscle background uptake value. For other tissues, the maximum SUV value measured for the selected single VOI was used. If the TBR result was equal to or higher than 5, the lesion was identified as 64 CuCl 2 Positive uptake (i.e. 64 CuCl 2 If the TBR is less than 5, the lesion is defined as 64 CuCl 2 Uptake negative.

[0078] According to one embodiment of the present invention, TBR is used as an objective parameter for patient selection.

[0079] Patients were selected for treatment if they had at least one lesion with a TBR equal to or higher than 5. Patients were not selected for treatment if they had no lesions with a TBR equal to or higher than 5.

[0080] Furthermore, TBR analyzed in PET / CT or PET / MRI after the first administration of the composition is also used as an objective parameter for predicting treatment response.

[0081] The results reported in the Examples section show that the TBR of non-responding patients is higher than that of responding patients. Specifically, according to clinical data, a TBR value > 25 indicates that the patient is non-responding, while a TBR value between 5 and 25 indicates that the patient is responding.

[0082] Therefore, in addition to being an indicator of tumor uptake in patients, TBR can also be used as 64 CuCl 2 Predictors of treatment response. PET / CT or PET / MRI results are acceptable for selection 64 CuCl 2 It is very helpful to treat the right patients, thus avoiding the risk of patients receiving unsuccessful treatment.

[0083] The assessment may be an empirical assessment of copper-64 uptake. The PET / CT or PET / MRI output may display an output that does not require physician interpretation. Thus, in one embodiment of the invention, the method includes the step of assessing copper-64 uptake as a computer output that is at a certain predetermined threshold. Copper-64 uptake and TBR assessed in this manner may be used as eligibility criteria for treatment.

[0084] The purpose of this method is to select 64 CuCl 2 Treat patients who respond well.

[0085] A "good responder" patient is a patient selected from the population who has a better response to treatment than patients not selected by the above methods (random selection) and / or who has fewer side effects / adverse events to treatment than patients not selected by the above methods (random selection).

[0086] In fact, PET / CT and / or PET / MRI can achieve this selection, but different imaging modalities (i.e., MRI, CT, bone scan, or PET / CT using other radioactive compounds than the radioisotope 64Cu) do not allow the selection of patients for treatment, because it is not possible to show whether the drug can be taken up by the tumor cells of a particular patient and therefore it is not possible to predict whether this patient will benefit from the treatment. The selection step is necessary to avoid the risk of starting patients on unsuccessful and toxic treatments.

[0087] If the patient turns out to be suitable for treatment and is selected to receive treatment, the method further comprises administering a therapeutically effective amount of 64 CuCl 2 The step of treating cancer in the patient selected for treatment can be initiated on the day of the selected administration, or 1 day to 4 weeks after the selected administration.

[0088] The inventors have shown that certain concentrations and amounts of copper-64 can be used in methods of treating a neoplasm that is capable of internalizing copper-64. Thus, the neoplasm is a particular neoplasm that is more sensitive to copper-64 treatment. Thus, one embodiment of the present invention relates to the use of copper-64 to treat a neoplasm that is capable of internalizing copper-64. Another embodiment of the present invention relates to the use of copper-64 to prepare a medicament for treating a neoplasm that is capable of internalizing copper-64.

[0089] According to a specific embodiment of the present invention, the aforementioned step a) may be optionally performed before the following steps:

[0090] i) collecting blood samples from human subjects;

[0091] ii) detecting the chemical copper content in the sample;

[0092] Wherein, step (c) is performed only when the serum copper level detected in the sample exceeds the normal range.

[0093] The purpose of step (ii) is to measure the copper level in the blood because it can serve as a biomarker for tumor activity. Specifically, circulating copper levels above the normal range indicate increased copper usage by tumor cells. Maximum serum copper levels in the blood may vary depending on the analytical method used to measure them. Serum copper levels above the normal range are above 60 μg / dL, optionally above 150 μg / dL.

[0094] According to one embodiment of the present invention, if the serum copper level in a blood sample of a human subject with a neoplasm is above 60 μg / dL, preferably above 150 μg / dL, the subject is treated by administering a therapeutically effective amount of a radiopharmaceutical composition comprising as an active ingredient copper-64( 64 Cu ++ ), in combination with suitable excipients and / or diluents, having a radioactivity concentration of between 50 and 3,500 MBq / mL at the calibration time. Thus, the inventors have shown that high levels of copper in the blood can be used as a positive indicator of the outcome of copper-64 treatment. Thus, if the subject has an elevated blood copper level, the vegetation is a particular vegetation that is more sensitive to copper-64 treatment. One embodiment of the present invention relates to a method for treating a vegetation in an individual with elevated blood copper levels, as described above. Thus, one embodiment of the present invention relates to the use of copper-64 for treating a vegetation in an individual with elevated blood copper levels. Another embodiment of the present invention relates to the use of copper-64 for the preparation of a medicament for treating a vegetation in an individual with elevated blood copper levels.

[0095] According to one embodiment of the present invention, in order to achieve a safe and effective effect in the therapeutic range, the dose that can be injected is a minimum of 7 MBq / kg to a maximum of 210 MBq / kg.

[0096] According to a specific embodiment of the present invention, in order to achieve a safe and effective effect in the therapeutic range, the dose that can be injected is a minimum of 13 MBq / kg to a maximum of 105 MBq / kg.

[0097] The dosage will be calculated based on the subject's weight. For example, a patient weighing 70 kg can receive a dosage between 1,850 MBq and 4,810 MBq. For a child weighing 25 kg, the dosage can be between 325 MBq and 2,625 MBq. In a specific embodiment, the subject is administered a therapeutically effective amount of the composition 1 to 7 times per treatment cycle. The cycle can be repeated more than once, preferably from one cycle to seven cycles. The frequency of administration can include 1 to 3 administrations per week. For each treatment cycle, the dosing regimen can include administering an increasing dose or a fixed dose to the patient. Each cycle should generally be separated by at least 15 days from the next cycle.

[0098] If an ascending dose regimen is used, the first dose is usually the initial treatment dose (X 1 ), and the following doses can be calculated as follows:

[0099] First dose <![CDATA[X 1 MBq]]> Dose 2 <![CDATA[X 2 =(X 1 +33%of X 1 )MBq]]> Dose 3 <![CDATA[X 3 =(X 2 +25%of X 1 )MBq]]> Dose 4 <![CDATA[X 4 =(X 3 +20%of X 1 )MBq]]> Dose 5 <![CDATA[X 5 =(X 4 +17%of X 1 )MBq]]> Dose 6 <![CDATA[X 6 =(X 5 +14%of X 1 )MBq]]> Dose 7 <![CDATA[X 7 =(X 6 +11%of X 1 )MBq]]>

[0100] An exemplary treatment regimen includes dosing an adult patient with the following per cycle: Dose 1 = 1,850 MBq, Dose 2 = 2,460 MBq, Dose 3 = 2,922 MBq, Dose 4 = 3,292 MBq, Dose 5 = 3,606 MBq, Dose 6 = 3,865 MBq, Dose 7 = 4,068 MBq, wherein the total activity administered equals 22,063 MBq per cycle.

[0101] Various exemplary treatment regimens include administering to an adult patient the following per cycle: Dose 1 = 4,810 MBq, Dose 2 = 4,810 MBq, Dose 3 = 4,810 MBq, Dose 4 = 4,810 MBq, Dose 5 = 4,810 MBq, Dose 6 = 4,810 MBq, Dose 7 = 4,810 MBq, wherein the total activity administered equals 33,670 MBq per cycle.

[0102] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of the volume of tumor lesions can be kept stable compared with the volume of lesions before treatment (no progression, no new lesions found, stable disease).

[0103] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of tumor lesion volume can be reduced by 50% compared with the lesion volume before treatment (lesion reduction, no new lesions, partial response).

[0104] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of tumor lesion volume can be reduced by 60% compared with the lesion volume before treatment (lesion reduction, no new lesions, partial response).

[0105] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of tumor lesion volume can be reduced by 70% compared with the lesion volume before treatment (lesion reduction, no new lesions, partial response).

[0106] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of tumor lesion volume can be reduced by 80% compared with the lesion volume before treatment (lesion reduction, no new lesions, partial response).

[0107] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of tumor lesion volume can be reduced by 90% compared with the lesion volume before treatment (lesion reduction, no new lesions, partial response).

[0108] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The incidence of tumor lesion volume can be reduced by 95% compared with the lesion volume before treatment (lesion reduction, no new lesions, partial response).

[0109] In certain aspects, administration to a subject who has chosen to undergo such treatment 64 CuCl 2 The volume of tumor lesions can be reduced by 100% compared with the volume of lesions before treatment (lesions disappear, no new lesions, complete response).

[0110] In certain embodiments, the subject who has been selected for such treatment is administered 64 CuCl 2 The subject's tumor growth can be inhibited and / or delayed and / or reduced. In certain aspects, tumor growth is delayed by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% compared to the predicted growth of the untreated tumor.

[0111] In certain embodiments, administering a drug to a subject who has chosen to undergo the treatment can increase the subject's survival time, compared to the predicted survival time of an untreated subject. In certain aspects, the survival length is increased by at least 30 days, 60 days, 90 days, 180 days, 365 days, 547 days, 730 days, compared to the predicted survival length of an untreated subject.

[0112] According to one embodiment, the cycle can be repeated more than once before selecting the patient for the next treatment cycle, and the use is performed at least 15 days and preferably 30 days after the end of the previous treatment. 64 CuCl 2 PET / CT or PET / MRI and / or conventional imaging (e.g., MRI, CT, SPECT, US, PET, with other radioisotopes than Cu-64) of the patient's choice. If the PET / CT or PET / MRI and / or conventional imaging (e.g., MRI, CT, SPECT, US, PET, with other radioisotopes than Cu-64) assessment shows a response to treatment (as defined above), the patient may proceed to the next treatment cycle. Treatment and dose calculations can be applied to both adult patients and the pediatric population.

[0113] These doses and dosage regimens have never been tested for efficacy and safety and are not derived from preclinical literature data. In fact, starting from all the preclinical data, it is possible to extrapolate and estimate the dose that can be injected into patients, extrapolating to take into account the differences in organ weights between humans and animals, assuming similar kinetic trends. The inventors performed simulations using the OLINDA software, taking into account possible variations in organs exposed to greater risk, namely the kidneys in mice and the liver in humans (Linder et al., 1998). However, this extrapolation cannot be transferred to humans, since the conversion doses in humans are very high. Therefore, the doses are defined starting from the diagnostic dose.

[0114] Furthermore, this is the first time that the safety profile and dose-limiting toxicities have been evaluated. No treatment-related toxicities related to liver / kidney and red bone marrow distribution were recorded.

[0115] The present disclosure also relates to a pharmaceutical composition as described in the previous section for use as a PET / CT or PET / MRI imaging agent for monitoring and determining whether a subject is sensitive to 64 CuCl 2 Responded to treatment.

[0116] After each treatment injection, the subject can be examined with PET / CT or PET / MRI to monitor the treatment response without the need to inject additional tracers. Monitoring the treatment response allows for control of disease trends and the body's response to treatment, including monitoring for possible toxicity and assessing biodistribution. So, for example, after the 4th treatment dose in the first round of treatment, the physician decides to perform a PET / CT scan to assess whether to continue treatment or interrupt treatment, preventing patients who do not respond to treatment from continuing treatment.

[0117] Results of PET / CT or PET / MRI imaging can be compared with standard imaging, such as MRI, CT, SPECT, US, PET, using radioisotopes other than Cu-64. 64 CuCl 2 PET technology for treatment response.

[0118] The human subjects treated can be male or female and can be adult patients or children.

[0119] According to one embodiment of the present invention, the neoplasms that can be treated with the radiopharmaceutical composition of the present invention can be in situ neoplasms, malignant neoplasms, and neoplasms of uncertain or unknown behavior. Malignant neoplasms are also referred to as "cancer" or "carcinoma". Considering that tumor cells internalize 64 Cu has the same mechanism and the invention can be used for all cancers or tumor types that are able to take up copper. Examples of cancers that can be treated with the radiopharmaceutical composition of the invention are pancreatic cancer, prostate cancer, brain cancer, especially glioblastoma and astrocytoma, breast cancer, ovarian cancer, genitourinary cancer, head and neck cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer and lung cancer, as well as melanoma, leukemia and lymphoma.

[0120] One of the objects of the present invention is to use the radiopharmaceutical composition as described above as a medicament for the treatment of head and neck cancer or brain cancer, in particular glioma, glioblastoma or astrocytoma.

[0121] Another object of the invention is a radiopharmaceutical composition as described above, for use as a medicament in the treatment of prostate cancer or metastatic prostate cancer.

[0122] Another object of the present invention is a radiopharmaceutical composition as described above, for use as a medicament for the treatment of breast or ovarian cancer.

[0123] Another object of the present invention is a radiopharmaceutical composition as described above, for use as a medicament for the treatment of esophageal cancer, gastric cancer, intestinal cancer or colon cancer.

[0124] Another object of the present invention is a radiopharmaceutical composition as described above, for use as a medicament for the treatment of lung cancer.

[0125] Another object of the invention is a radiopharmaceutical composition as described above, for use as a medicament for the treatment of leukemia or lymphoma.

[0126] Another object of the invention is a radiopharmaceutical composition as described above, for use as a medicament in the treatment of neuroendocrine tumors.

[0127] Another object of the invention is a radiopharmaceutical composition as described above, for use as a medicament for the treatment of melanoma.

[0128] A particular object of the present invention is a radiopharmaceutical composition comprising as active ingredient copper-64 ( 64 Cu ++ ), combined with a suitable excipient and / or diluent, dissolved in a saline solution having a radioactivity concentration of 2,775 MBq / mL when calibrated, for use as a medicament for treating glioblastoma, wherein the composition is administered by injection.

[0129] A particular object of the present invention is a radiopharmaceutical composition comprising as active ingredient copper-64 ( 64 Cu ++ ), combined with a suitable excipient and / or diluent, dissolved in a saline solution having a radioactivity concentration of 2,775 MBq / mL when calibrated, for use as a medicament for treating prostate cancer or metastatic prostate cancer, wherein the composition is administered by injection.

[0130] The possibility of using this combination in different tumor types is related to the mechanism of copper internalization in tumor cells, which is independent of the tumor type. In fact, the copper content in tumors is higher than in normal cells, 64 Cu 2+ Following this unusual copper homeostasis, replacing the chemical Cu 2+ Ions. In the blood, 64 Cu 2+ Ions can bind to plasma proteins (such as ceruloplasmin, albumin, and transferrin), which transfer 6 64 Cu 2+ ions are transferred to the outer cell membrane, where they are reduced by reductases to 64 Cu + ions. In this reduced-oxidation state, Cu + The ion is then transported across the cell membrane by human copper transporter 1 (CTR1). Once inside the cell, copper transport is mediated by chaperones, which are usually located in the Cu + Once inside the cell, it is immediately received. These molecular chaperones convert Cu +Ion transport to the cytoplasm SOD1, cytochrome C oxidase (COX) in the mitochondria, ATP7A and ATP7B are responsible for transporting copper to the trans-Golgi network and antioxidant protein (ATOX1) to the nucleus (Boschi et al., 2018).

[0131] 64 CuCl 2 Evidence for internalization in tumor cells comes not only from preclinical studies with microPET, but also from clinical studies. Jorgensen and his collaborators used microPET to study the effects of microPET on the internalization of tumor cells in mice injected with 64 CuCl 2 After transplantation of a series of mice with five human neoplastic cell lines, including ovarian cancer, head and neck tumors, neuroendocrine lung cancer, colorectal cancer, and glioblastoma, the results showed that the tumor tissues took up a large amount of 64 Cu 2+ (Jorgensen et al., 2013). 64 CuCl 2 The ability to act as a tracer of copper homeostasis has also been demonstrated in clinical settings, such as prostate cancer (Piccardo et al., 2017), glioblastoma (Panichelli et al., 2016), urological malignancies (Mascia et al., 2021), and non-small cell lung cancer (García-Pérez et al., 2020), demonstrating that the radioisotope is able to enter tumor cells of very different types of tumors.

[0132] Several studies have compared tumor cells to 64 CuCl 2 The uptake of CTR1 in tumours has been linked to its overexpression, demonstrating its potential as a promising target for molecular imaging and its potential in the treatment of 64 CuCl 2 It has a selective effect on tumor cells.

[0133] In the study by Kim et al., in human breast cancer cells, 64 CuCl 2 Increased uptake is associated with CTR1 overexpression (Kim et al., 2014), and it has been demonstrated that inhibition of CTR1 in prostate cancer leads to 64 CuCl 2 Reduced uptake (Cai et al., 2014). CTR1 is involved 64 CuCl 2Uptake has also been demonstrated in other tumor types such as hepatocellular carcinoma (Peng et al., 2005), prostate cancer (Peng et al., 2006; Cai et al., 2014), melanoma (Qin et al., 2014), neuroblastoma (Pamar et al., 2018), lung cancer (Wang et al., 2020), ovarian cancer, head and neck cancer, colorectal cancer, and glioblastoma (Jorgensen et al., 2013).

[0134] Other transporters / chaperones can affect 64 Cu uptake, such as ATOX1, which is overexpressed in different tumor types such as colorectal cancer, breast cancer, lung cancer, melanoma, etc., and is involved in copper transport (Cai H et al., 2013; Beaino et al., 2014; Karginova et al., 2019; Kim et al., 2019).

[0135] Considering that CTR1 and ATOX1 are 64 CuCl 2 They have the potential to be predictive biomarkers of treatment response and useful biomarkers for patient selection.

[0136] Finally, internalization 64 CuCl 2 Tumors with CT scans or PET / MRI that have successfully visualized the tracer can be used 64 CuCl 2 treatment, which highlights the use of 64 CuCl 2 Great potential as a diagnostic agent.

[0137] The radiopharmaceutical compositions and methods of the present invention can make a significant contribution to patient care compared to existing therapies. In particular, compared to other radiopharmaceutical treatments defined as diagnostic, which contemplate the injection of two different doses and two different compounds, the methods of the present invention envisage using the same radiopharmaceutical to select a subject to be treated, treat the selected subject and monitor the subject's response to the treatment; this provides the following advantages to the patient:

[0138] Reduced adverse effects of multiple drug interactions: This approach can reduce the risk of adverse events associated with drug interactions by avoiding injections of different compounds without the need to inject another PET / CT imaging agent for diagnosis or monitoring of treatment response

[0139] Real-time monitoring of treatment response: During treatment, there is no need to inject another dose of another radiopharmaceutical to monitor the treatment response: This treatment method has a great advantage that through PET / CT scanning, the drug effect can be monitored in real time during the treatment process as long as the clinician maintains appropriate status. This is crucial for personalized medicine. In fact, controlling the treatment response allows doctors to decide whether to interrupt the treatment that is not working for the patient or continue the treatment without wasting time waiting for the administration of another therapeutic agent. For example, after injecting the 4th treatment dose of 64 CuCl 2 Afterwards, PET / CT can be performed without injecting a different drug to evaluate tumor response.

[0140] Prediction of the right treatment choice: With the first diagnostic injection, the physician can verify whether the patient is suitable for starting treatment. If there is no uptake of the first injection, the patient can be switched to another treatment, on the other hand, if the uptake is significant, a good effect of the treatment can be expected. Therefore, this is a method to quickly predict whether a treatment will work for a specific subject

[0141] Improved patient compliance: If the same drug is available for multiple ranges, the patient will show higher compliance because he will have more confidence in the drug that he has already injected and has no side effects. In addition, the patient also appreciates the reduction in the number of drugs to receive

[0142] Reduced exposure of hospital personnel: Using the same tracer for diagnosis, treatment, and monitoring of treatment response reduces exposure of personnel during product handling steps (e.g., reducing exposure during preparation of different doses)

[0143] definition

[0144] “Theranostics” (or “theranostics / theranostics” approach) refers here to a treatment strategy that combines therapeutics with diagnostics. It includes both diagnostic tests to identify patients most likely to benefit or be harmed by new drugs and targeted drug therapies based on the test results.

[0145] "Neoplasia" here refers to an abnormal and excessive growth of tissue. This abnormal growth usually forms a mass, sometimes also called a "tumor". The process of forming or producing a neoplasm is called "neoplasm formation". According to ICD-10 (Neoplasia - 2010 International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) version. World Health Organization. Retrieval date: June 19, 2014), neoplasms are divided into four major categories: benign neoplasms, in situ neoplasms, malignant neoplasms and neoplasms of unclear or unknown behavior. Malignant neoplasms are also referred to as "cancer" or "cancer" for short.

[0146] According to the present invention, the expressions "therapy" or "treatment" are intended to refer to activities intended to cure, ameliorate, inhibit or alleviate the symptoms or slow the progression of a disease or pathological condition.

[0147] Expressions such as "radiopharmaceutical" compositions herein are intended to refer to pharmaceutical compositions that contain a radioactive isotope.

[0148] According to the present invention, the expression "radioactivity concentration" and the like is intended to refer to the concentration of the radioisotope. It is measured in mCi / mL or MBq / mL at the time of calibration (TOC), usually at the end of synthesis (EOS).

[0149] As used herein, "excipient" and like terms are intended to refer to conventional excipients, ie, compounds that are inert toward the active ingredients of the composition.

[0150] The invention will now be described by reference to the following non-limiting examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0151] Figure 1 – Effects of different radioactivity concentrations on tumor cell uptake

[0152] Different tumor cell lines U87MG, PC-3, CAMA1, C8161, HT-29 64 CuCl 2 Cellular uptake. Cells were treated with the same dose (15 MBq / dish 100 mm) but with three different radioactivity concentrations C1 = 925 MBq / mL, C2 = 1,850 MBq / mL, C3 = 2,775 MBq / mL, and cellular uptake was evaluated. Values ​​are expressed as mean ± SEM.

[0153] Figure 2 – Effects of different radioactivity concentrations on tumor cell survival

[0154] Survival curves of U87MG treated with the same dose range but at three different concentrations C1 = 925 MBq / mL, C2 = 1,850 MBq / mL, C3 = 2,775 MBq / mL. Values ​​are expressed as mean ± SEM. (**p≤0.01 ***p≤0.001 compared to cells treated with C1). D0 = untreated, D1 = 0.0034 MBq, D2 = 0.034, D3 = 0.34, D4 = 1.7 MBq, D5 = 3.4 MBq. C3 has an improved cell killing effect of about 30% at D4 and D5 compared to C1.

[0155] Figure 3 – 64 CuCl 2 Tumor size decreased after treatment

[0156] Graphical representation of tumor volume reduction of lesions from a single glioblastoma patient evaluated by MRI. Volume was assessed on day 0 (before treatment started), day 42 (after 7 treatments of 64CuCl2), and day 90 (3-month follow-up). The patient was treated with a fixed dose of 4,810 MBq, once a week for 7 weeks. X-axis: MRI examination day 0 = before treatment started, day 42 = after 7 treatments, day 90 = 3 months after treatment ended, day 180 = 6 months after treatment ended. Y-axis: sum of the products of the perpendicular diameters of all measurable enhancing lesions

[0157] Figure 4 – MRI before and after treatment

[0158] 7 fixed doses once a week 64 CuCl 2 MRI of a glioblastoma patient treated with 4,810MBq.

[0159] The left image is an MRI performed before starting treatment, and the right image is an MRI performed 90 days after starting treatment. The patient responded to treatment, as evidenced by a >50% reduction in tumor volume following treatment. DETAILED DESCRIPTION

[0160] Example

[0161] Example 1 - Composition used in the selection step

[0162] In the selection step, an effective amount of 64 CuCl 2 Administration as a contrast agent for PET / CT or PET / MRI imaging. Drugs for use in the selection step 64 CuCl 2 The composition is a ready-to-use injection (intravenous injection) as a single-dose product or a multi-dose product, whose radioactivity concentration is 930MBq / mL to 3,500MBq / mL, preferably 2,775MBq / mL at the calibration date and time. The volume of the single-dose injection varies from 0.5 to 20mL.

[0163] The drug synthesis steps are carried out in a closed system synthesis module, which is automatically remotely controlled by GMP-compliant software and automatically monitors and records process parameters. Considering the nature of the product (radioactivity), the radionuclides will decay naturally, which is the characteristic of radiopharmaceuticals, so the radioactivity concentration will change over time, which is why the above radioactivity concentrations refer to the calibration time.

[0164] Example 2 - Compositions used in treatment procedures

[0165] Drugs used in treatment procedures 64 CuCl 2The composition is a ready-to-use injection (intravenous) solution, as a single-dose product or a multi-dose product, with a radioactivity concentration of 930 MBq / mL to 3,500 MBq / mL at the calibration date and time. The volume of the single-dose injection solution varies from 0.5 to 20 mL. The solution can be diluted with 0.9% NaCl before administration.

[0166] Alternatively, the drug used in the treatment procedure 64 CuCl 2 The composition is a ready-to-use infusion solution with a radioactivity concentration ranging from 50 MBq / mL to 925 MB / mL when calibrated. The volume of a single dose infusion solution ranges from 5 to 30 mL.

[0167] The drug synthesis steps are carried out in a closed system synthesis module, which is automatically remotely controlled by GMP-compliant software and automatically monitors and records process parameters. Considering the nature of the product (radioactivity), the radionuclides will decay naturally, which is the characteristic of radiopharmaceuticals, so the radioactivity concentration will change over time, which is why the above radioactivity concentrations refer to the calibration time.

[0168] Example 3 - Use 64 CuCl 2 Treatment options for human patients

[0169] In the current protocol, the drugs used are radioactive concentrations ranging from 930MBq / mL to 3,500MBq / mL. 64 CuCl 2 , as an injection and a single-dose product. The half-life of copper-64 is 12.7 hours.

[0170] Step a: administering an effective amount of 64 CuCl 2 As a contrast agent for PET / CT or PET / MRI imaging

[0171] Patients with tumors received doses of 370–925 MBq 64 CuCl 2 , to ensure proper image quality. The calculated 64 CuCl 2 The average effective dose was 20 mSv per examination, which is consistent with the dose of conventional PET imaging.

[0172] Step b: Use 64 CuCl 2 Obtain PET / CT or PET / MRI imaging and select patients for treatment

[0173] Injection 64 CuCl 2PET / CT or PET / MRI imaging is performed 1 hour after the procedure. If PET / CT imaging is obtained, the parameters for CT (AC / AL) are: 100 mAs (adjustable based on body weight), 130 kVa, 5 mm serial slices. After the CT acquisition is complete, the PET acquisition consists of 2 iterations, 8 subsets, 128 acquisition matrices. The acquisition time for each PET bad site is 3-4 minutes, and the total scan time is 15-20 minutes. After the PET / CT or PET / MRI scan, the imaging is evaluated to identify lesions and observe the patient's cancer lesions. 64 CuCl 2 SUV of the lesion was measured max and SUVs of specific "background organizations" background , to calculate the target-to-background ratio (TBR). If the TBR result is equal to or higher than 5, the patient's lesion is judged to be 64 CuCl 2 Positive uptake (i.e., indicating uptake of 64 CuCl 2 ). In this case, subjects showing copper-64 uptake are eligible and can continue treatment.

[0174] Step c: Use 64 CuCl 2 treat

[0175] Treatment can start on the day of the diagnostic dose and last up to 30 days after the diagnostic dose. Patients with positive tumor lesions as determined in step b) receive parenteral administration of 1,850 MBq–4,810 MBq of 64 CuCl 2 The therapeutic dose is given in 1-7 divided doses.

[0176] According to nuclear medicine clinical practice, a range of ±10% for each administered dose is acceptable and does not pose any risk to patient safety.

[0177] Monitoring can be performed during treatment, and PET / CT or PET / MRI can be performed on the day of injection of the therapeutic dose.

[0178] Example 4 - Selection of cancer patients for TBR treatment

[0179] Based on dosimetry evaluations from two different Phase I clinical trials, 64 CuCl 2In a preliminary capacity as a diagnostic agent in 16 glioblastoma patients and 16 prostate cancer patients, the TBR obtained from the PET / CT scans performed during the selection / qualification step also correlated with the response to copper chloride treatment. These results showed that the TBR of non-responding patients was higher than that of responding patients, especially that TBR values ​​>25 resulted in non-responding patients, while TBRs from 5 to 25 resulted in patients being classified as responding patients, based on clinical data. Therefore, TBR, in addition to representing an index of tumor uptake in patients, can also be used as an index of 64 CuCl 2 Predictive indices for treatment response. PET / CT or PET / MRI results are important for selecting appropriate patients to start 64 CuCl 2 Treatment is critical to avoid putting patients at risk of starting unsuccessful treatment.

[0180] Example 5 - Pharmacokinetic profile of the composition

[0181] Safety was evaluated in six glioblastoma patients, and a biodistribution study was performed, including evaluation of PET / CT scans after the first daily dose of the radiopharmaceutical composition, which had a radioactivity concentration of 2,775MBq / mL (Day 0), pharmacokinetic (PK) radioactivity at various time points after injection, 1 hour, 4 hours, 24 hours, and 48 hours, and blood samples at various time points of administration.

[0182] In this study 64 The pharmacokinetic profile of Cu showed that 64 Cu uptake increased within 4 hours after injection and decreased thereafter, indicating in vivo stability of this theranostic radiopharmaceutical. The data showed significant uptake in the liver (as expected), followed by the kidneys and L2-L4 regions. No treatment-related toxicity was found with regard to liver / kidney and red bone marrow distribution. The effective dose ranged from 0.27 to 45.44 mSv with a median of 26.08 mSv. These values ​​are considered acceptable for diagnostic applications.

[0183] Example 6 - Glioblastoma patients 64 CuCl 2 Response to treatment

[0184] A 70 kg glioblastoma patient had recurrent glioblastoma. The patient underwent surgery, radiotherapy, and chemotherapy, but relapsed. Standard treatment was ineffective in this case, so the patient received a diagnostic dose of 925 MBq of 64 CuCl 2 . A PET / CT scan was performed 1 hour after dosing. The patient tested positive for copper lesions at the diagnostic dose and was started on treatment

[0185] 6 64 CuCl 2(2,775MBq / mL) IV treatment followed the following schedule, with patients receiving once weekly:

[0186] First dose = 4,810MBq, second dose = 4,810MBq, third dose = 4,810MBq, fourth dose = 4,810MBq, fifth dose = 4,810MBq, sixth dose = 4,810MBq, seventh dose = 4,810MBq

[0187] The total activity administered was equal to 33,670 MBq x cycle.

[0188] Figure 3 The efficacy of this radiopharmaceutical composition at these dose ranges and dose intervals was demonstrated. The radiopharmaceutical composition tested with this dose regimen demonstrated the ability to induce a reduction in tumor volume. Specifically, standard imaging (MRI) showed a greater than 50% reduction in tumor volume (day 90) 3 months after the start of treatment. Figure 4 ).

[0189] Example 7 - Treatment of prostate cancer patients belonging to the category of metastatic prostate cancer

[0190] The patient had localized tumors at initial diagnosis and was treated with surgery (radical prostatectomy) followed by radiation and chemotherapy. However, he experienced local recurrence and bone metastatic disease. After all standard treatments, the patient received a diagnostic dose of 64 CuCl 2 , equivalent to 925MBq. A PET / CT scan was performed 1 hour after dosing. The patient tested positive for copper lesions at the diagnostic dose and treatment was initiated.

[0191] use 64 CuCl 2 (2,775 MBq / mL) composition was administered as an injection once a week following the following regimen:

[0192] 1st dose = 4,810MBq, 2nd dose = 4,810MBq, 3rd dose = 4,810MBq, 4th dose = 4,810MBq, 5th dose = 4,810MBq, 6th dose = 4,810MBq, 7th dose = 4,810MBq

[0193] The total activity administered was equal to 33,670 MBq x cycle.

[0194] After treatment, PET / CT analysis before and after treatment showed a reduction in tumor lesions on the bones, indicating that the composition had a therapeutic effect.

[0195] Example 8 - Treatment of glioblastoma patients belonging to the recurrent glioblastoma class

[0196] The patient (71 kg) underwent surgery, radiotherapy, and chemotherapy, but relapsed. Standard treatment was ineffective in this setting, so the patient received a diagnostic dose of 64 CuCl 2 , equivalent to 925MBq. A PET / CT scan was performed 1 hour after dosing. The patient was positive for copper lesions at the diagnostic dose and treatment was initiated (i.v. 64 CuCl 2 277MBq / mL).

[0197] Treatment followed the following regimen, with patients receiving it once a week:

[0198] 1st dose = 1,850MBq, 2nd dose = 2,460MBq, 3rd dose = 2,922MBq, 4th dose = 3,292MBq, 5th dose = 3,606MBq, 6th dose = 3,865MBq, 7th dose = 4,068MBq.

[0199] The total dose administered per cycle equaled 22,063 MBq.

[0200] The patient responded to treatment.

[0201] Example 9 - Treatment of Pediatric Patients with High-Grade Glioma

[0202] Patients (25 kg) received a diagnostic dose of 64 CuCl 2 , equivalent to 132.5MBq. A PET / CT scan was performed 1 hour after dosing. The child tested positive for copper lesions at the diagnostic dose and treatment was initiated.

[0203] Patients received treatment three times a week with the following regimen:

[0204] 1st dose = 1,700MBq, 2nd dose = 1,700MBq, 3rd dose = 1,700MBq, 4th dose = 1,700MBq, 5th dose = 1,700MBq, 6th dose = 1,700MBq, 7th dose = 1,700MBq

[0205] Here, the total activity administered equals 11,900 MBq x cycle.

[0206] The composition is 64 CuCl 2 925MBq / mL, for intravenous infusion.

[0207] Example 10 - 7 doses 64 CuCl 2 Post-treatment response

[0208] Phase I clinical trial in glioblastoma is the first to evaluate 64 CuCl 2The preliminary efficacy study of 2,775 MBq / mL as a therapeutic agent was conducted in 10 patients, at the end of treatment 7, at day 90 (3 months after the last treatment), and whenever possible at day 180 to more extensively assess disease status. Data were truncated after 5 patients. 64 CuCl 2 Treatment response was measured by anti-tumor activity measured by MRI, assessed according to the RANO criteria (Response Assessment in Neuro-Oncology, see Wen PY et al.), defined as complete response (tumor disappearance), partial response (shrinkage), and stable disease (no GBM progression). Four of these patients responded and one did not respond. All patients received 7 64 CuCl 2 Evaluations were performed after treatment, and MRI evaluations of responding patients showed that at the 42-day evaluation, three patients had stable disease and one patient had a 50% reduction in tumor volume compared to baseline MRI. Two patients had a ≥50% reduction in tumor volume three months after the last treatment, and one patient had a ≥50% reduction in tumor volume six months after the last treatment. In addition, two patients had stable disease at day 90, and one patient had stable disease six months after treatment.

[0209] Example 11 - Monitoring Treatment Response

[0210] PET / CT (or PET / MRI) can be used to monitor treatment response without injecting additional tracers, but by obtaining PET / CT after the drug is administered. 64 CuCl 2 In patients with glioblastoma treated with MRI, PET / CT was obtained at the end of the seventh treatment dose. MRI was also performed in conjunction with standard imaging. 64 CuCl 2 Treatment response in terms of antitumor activity was assessed according to RANO criteria and defined as complete response (tumor disappearance), partial response (reduction), and stable disease (GBM progression-free). Two external assessors analyzed the number of lesions, lesion localization, SUVmax lesions, SUVbackground, and TBR in PET / CT imaging. Treatment response was also measured by PET / CT. Comparison of the analysis obtained with standard imaging MRI with that obtained with PET / CT imaging showed consistent localization of tumor lesions and overlapping classification of treatment response, indicating that 64 CuCl 2 PET / CT is a technique that can be used to monitor treatment response. This method can be applied to all tumor lines that are able to take up copper-64.

[0211] Example 12-4 dose 64 CuCl 2 Post-treatment response

[0212] Five patients with prostate cancer received four injections 64 CuCl 2 Treatment with 2,775MBq / mL injection showed a therapeutic response. Two independent observers analyzed the PET / CT obtained on the day of the fourth treatment administration and the PET / CT obtained before the start of treatment (another evaluation was expressed by a third observer only if there was a difference). After 4 doses, the lesion volume showed a decrease or no progression, indicating that the treatment was effective.

[0213] bibliography

[0214] Bai Y,Wang G,Fu W,Lu Y,Wei W,Chen W,Wu X,Meng H,Feng Y,Liu Y,Li G,Wang S,Wang K,Dai J,Li H,Li M,Huang J,Li Y,Wei S,Yuan J,Yao P,Miao potential molecular effects.Environ Int.2019 Jun;127:685-693.

[0215] Ballinger JR.Theranostic radiopharmaceuticals:established agents incurrent use.Br J Radiol.2018Nov;91(1091):20170969.doi:10.1259 / bjr.20170969.Epub 2018Mar 12.PMID:29474096;PMCID:PMC6475961.

[0216] Beaino W, Guo Y, Chang AJ, Anderson CJ. Roles of Atox1 and p53 in the trafficking of copper-64to tumor cell nuclei:implications for cancer therapy. J Biol Inorg Chem. 2014 Mar;19(3):427-38.

[0217] Cai H, Wu JS, Muzik O, Hsieh JT, Lee RJ, Peng F. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med. 2014;55:622–8.

[0218] Capasso E., Durzu S., Piras S et al., Role of 64CuCl2 PET / CT in staging of prostate cancer. Ann Nucl Med., 29:482–8, 2015;

[0219] Catalogna G., Talarico C. and Dattilo V. The SGK1 Kinase Inhibitor SI113 sensitizes the diagnostic effects of the 64CuCl2 in human glioblastoma multiforme cells. Cellular Physiology and Biochemistry, 43:108 - 119, 2017.

[0220] Ferrari C., Asabella AN. and Villano C. Copper - 64 dichloride as the diagnostic agent for glioblastoma multiforme: a preclinical study. Biomed Research International, 2015.

[0221] Fisher GL, Shifrine M(1978) Hypothesis for the mechanism of elevated serum copper in cancer patients. Oncology 35:22 - 25

[0222] Fuchs A,Lustig ED.Localization of tissue copper in mouse mammarytumors.Oncology 1989;46:183–7

[0223] García-Pérez FO,Medina-Ornelas SS,Barron-Barron F,Arrieta-RodriguezO.Evaluation of non-small cell lung cancer by PET / CT with 64CuCl2:initialexperience in humans.Am J Nucl Med Mol Imaging.2020 Jun 15;10(3):143-150.PMID:32704405;PMCID:PMC7364381.

[0224] Guerreiro JF,Alves V,Abrunhosa AJ,Paulo A,Gil OM,MendesF.Radiobiological Characterization of 64CuCl 2 as a Simple Tool for ProstateCancer Theragnostics.Molecules.2018Nov 11;23(11):2944.

[0225] Karginova O,Weekley CM,Raoul A,Alsayed A,Wu T,Lee SS,He C,OlopadeOI.Inhibition of Copper Transport Induces Apoptosis in Triple-Negative BreastCancer Cells and Suppresses Tumor Angiogenesis.Mol Cancer Ther.2019 May;18(5):873-885.doi:10.1158 / 1535-7163.MCT-18-0667.Epub 2019Mar 1.PMID:

[0226] Kim KI, Jang SJ, Park JH, Lee YJ, Lee TS, Woo KS et al., Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model. J Nucl Med Off Publ Soc Nucl Med. 2014;55:1692–8.

[0227] Howell R.W. Radiation spectra for Auger - electron emitting radionuclides: report No.2 of AAPM Nuclear Medicine Task Group No.6. Med Phys. 1992 Nov - Dec;19(6):1371 - 83.

[0228] Hu GF. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem. 1998 Jun 1;69(3):326 - 35.

[0229] Lapa C. Exciting Opportunities in Nuclear Medicine Imaging and Therapy. J Clin Med. 2019 Nov 12;8(11):1944. doi:10.3390 / jcm8111944. PMID:31718092; PMCID:PMC6912644.

[0230] Lelièvre P,Sancey L,Coll JL,Deniaud A,Busser B.The Multifaceted Rolesof Copper in Cancer:ATrace Metal Element with Dysregulated Metabolism,butAlso a Target or a Bullet for Therapy.Cancers(Basel).2020 Dec 1;12(12):3594.doi:10.3390 / cancers12123594.PMID:33271772;PMCID:PMC7760327.

[0231] Manjula S,Aroor AR,Raja A,Rao SN,Rao A.Elevation of serumceruloplasmin levels in brain tumours.Acta Neurol Scand.1992 Aug;86(2):156-8.doi:10.1111 / j.1600-0404.1992.tb05058.x.PMID:1414225.

[0232] Pamar et al.2018”In vivo[64Cu]CuCl2 PET imaging reveals activity ofDextran-Catechin on tumor copper homeostasis”

[0233] Panichelli P,Villano C,Cistaro A,Bruno A,Barbato F,Piccardo A,DuattiA.Imaging of Brain Tumors with Copper-64 Chloride:Early Experience andResults.Cancer Biother Radiopharm.2016 Jun;31(5):159-67

[0234] Peng F,Liu J,Wu JS,Lu X,Muzik O.Mouse extrahepatic hepatoma detectedon MicroPET using copper(II)-64 chloride uptake mediated by endogenous mousecopper transporter 1.Mol Imaging Biol.2005 Sep-Oct;7(5):325-9.

[0235] Peng F.,Lu X.and Janisse J.PET of human prostate cancer xenograftsmice with increased uptake of 64CuCl2.The jurnal of nuclear medicine,Vol 47n°10pp 1649-1652,2006.

[0236] Piccardo A, Paparo F, Points M, Righi S, Buttons G, Bacigalupo L, Zanardi S, DeCensi A, Ferrarazzo G, Gambaro M, Ruggieri FG, Campodonic F, Tomasello L, Timossi L, Sola S, Wolves E, Cabria M. Med.2018 Mar:59(3):444-451.doi:10.2967 / jnumed.117.195628.Epub 2017 Sep8.PMID:28887398.Pinto CIG,Bucar S,Alves V,SFonsereisaro AJ,Fbrunhos F.Copper-64 Chloride Exhibits Therapeutic Potential inThree-Dimensional Cellular Models of Prostate Cancer.Front Mol Biosci.2020Dec 1;7:609172.doi:10.3389 / fmolb.2020.609172.PMID:33335914;PMCID:PMC7736412.

[0237] Qin C,Liu H,Chen K,Hu X,Ma X,Lan X,Zhang Y,Cheng Z.Theragnostics ofmalignant melanoma with 64CuCl2.J Nucl Med.2014 May:55(5):812-7.doi:10.2967 Mar 30.13.1 13.PMID:24627435;PMCID:PMC4346241.

[0238] Saleh S,A,K,Adly H,M,Abdelkhaliq A,A,Nassir A,M:Serum Levels ofSelenium,Zinc,Copper,Manganese,and Iron in Prostate Cancer Patients.Curr Urol2020;14:44-49.doi:10.1159 / 000499261

[0239] Scanni A,Tomirotti M,Licciardello L,Annibali E,Biraghi M,Trovato M,Fittipaldi M,Adamoli P,Curtarello G(1979)Variations in serum copper andceruloplasmin levels in advanced gastrointestinal cancer treated withpolychemotherapy.Tumori 65:331 338.

[0240] Wang Q,Song D,Ma X,Wu X,Jiang L.Preclinical PET imaging study of lungcancer with 64CuCl2.Ann Nucl Med.2020 Sep;34(9):653-662.doi:10.1007 / s12149-020-01491-6.Epub 2020 Jun 21.PMID:32567008.

[0241] Wen PY,Chang SM,Van den Bent MJ,Vogelbaum MA,Macdonald DR,LeeEQ.Response Assessment in Neuro-Oncology Clinical Trials.J Clin Oncol.2017Jul 20;35(21):2439-2449.

[0242] Zhang M,Shi M,Zhao Y.Association between serum copper levels andcervical cancer risk:a meta-analysis.Biosci Rep.2018;38(4):BSR20180161.Published 2018 Jul 6.

Claims

1. A radiopharmaceutical composition comprising as an active ingredient copper-64( 64 Cu ++ ), in combination with suitable excipients and / or diluents in saline solution, having a radioactivity concentration at calibration of between 50 and 3,500 MBq / mL, optionally equal to, below or above 925 MBq / mL.

2. The radiopharmaceutical composition according to claim 1 for use as a medicament.

3. The radiopharmaceutical composition of claim 1 or 2, wherein the radioactivity concentration during calibration is between 930 MBq / mL and 3,500 MBq / mL.

4. The radiopharmaceutical composition of any one of the preceding claims, wherein the radioactivity concentration at calibration is between 1,000 MBq / mL and 2,800 MBq / mL.

5. The radiopharmaceutical composition of any preceding claim, wherein the radioactivity concentration at calibration is between 1,850 MBq / mL and 2,775 MBq / mL.

6. The radiopharmaceutical composition of any preceding claim, wherein the radioactivity concentration upon calibration is 2,775 MBq / mL.

7. The radiopharmaceutical composition of any one of the preceding claims, wherein the radioactivity concentration at calibration is 1,850 MBq / mL.

8. The radiopharmaceutical composition of any one of the preceding claims, wherein the radioactivity concentration upon calibration is between 50 MBq / mL and 920 MBq / mL.

9. The radiopharmaceutical composition of any one of the preceding claims, wherein the radioactivity concentration upon calibration is between 100 MBq / mL and 600 MBq / mL.

10. The radiopharmaceutical composition of any preceding claim, wherein the radioactivity concentration at calibration is between 200 MBq / mL and 450 MBq / mL at calibration, optionally 350 MBq / mL at calibration.

11. A radiopharmaceutical composition according to any one of the preceding claims, having a specific activity between 64 Cu / μg copper ranges from 500 to 50,000 MBq.

12. A radiopharmaceutical composition according to any one of the preceding claims having a specific activity between 1,000 and 10,000 MBq 64Cu / microgram copper.

13. A radiopharmaceutical composition according to any one of the preceding claims, wherein the drug is directed against a neoplasm, such as a benign neoplasm, an in situ neoplasm, a malignant neoplasm or a neoplasm of uncertain or unknown behaviour.

14. The radiopharmaceutical composition according to any one of the preceding claims, wherein the malignant neoplasm is a head and neck cancer or a brain cancer, in particular a glioma, a glioblastoma or an astrocytoma.

15. The radiopharmaceutical composition of any one of the preceding claims, wherein the malignant neoplasm is prostate cancer or metastatic prostate cancer.

16. The radiopharmaceutical composition of any one of the preceding claims, wherein the malignant neoplasm is breast cancer or ovarian cancer.

17. The radiopharmaceutical composition of any one of the preceding claims, wherein the malignant neoplasm is esophageal cancer, gastric cancer, intestinal cancer or colon cancer.

18. The radiopharmaceutical composition of any one of the preceding claims, wherein the malignant neoplasm is lung cancer.

19. The radiopharmaceutical composition of any preceding claim, wherein the malignant neoplasm is a leukemia or a lymphoma.

20. The radiopharmaceutical composition of any one of the preceding claims, wherein the malignant neoplasm is a neuroendocrine tumor.

21. The radiopharmaceutical composition of any one of the preceding claims, wherein the malignant neoplasm is a melanoma.

22. The radiopharmaceutical composition of any one of the preceding claims, wherein the composition is administered enterally, parenterally, by inhalation, orally or transdermally.

23. The radiopharmaceutical composition according to any of the preceding claims, wherein the composition is administered by intramuscular, intradermal, subcutaneous, intratumoral, intracavitary and intrathecal or intravenous routes and any medical device system.

24. The radiopharmaceutical composition of any preceding claim, wherein the composition is administered intravenously by injection.

25. The radiopharmaceutical composition of any preceding claim, wherein the composition is administered intravenously by infusion.

26. The radiopharmaceutical composition of claims 1, 6, 14 and 24, wherein the radioactivity concentration at calibration is equal to 2,775 MBq / mL.

27. The radiopharmaceutical composition of claims 1, 6, 15 and 24, wherein the radioactivity concentration at calibration is equal to 2,775 MBq / mL.

28. The radiopharmaceutical composition of any one of the preceding claims, wherein the radioactivity concentration at calibration is equal to 925 MBq / mL and the composition is administered by infusion.

29. A radiopharmaceutical composition according to any preceding claim for use in a method of treating a neoplasm, wherein the treatment is preceded by a stage of assessing the subject's suitability for treatment.

30. The radiopharmaceutical composition of claim 29, wherein the stage of assessing whether a subject is suitable for treatment comprises determining whether the neoplastic cells are 64 Cu uptake.

31. The radiopharmaceutical composition of claim 29, wherein the neoplastic cells are determined to be 64 Cu uptake was measured by PET imaging with target-to-background ratio (TBR) values, where TBR values ​​equal to or greater than 5 were considered to demonstrate uptake by neoplastic cells. 64 Cu.

32. The radiopharmaceutical composition of claim 29, wherein the dose of the radiopharmaceutical composition is between 3 MBq / kg and 14 MBq / kg, optionally between 5.3 MBq / kg and 13 MBq / kg, for use in assessing whether a patient is suitable for treatment.

33. A radiopharmaceutical composition according to any one of the preceding claims for use in treating a neoplasm, wherein the treatment is followed by a period of monitoring the subject's response to the treatment.

34. The radiopharmaceutical composition of claim 29, wherein the copper level in the subject's blood sample is determined prior to the subject's suitability assessment phase, and the suitability assessment phase is performed only if the serum copper level detected in the patient's blood sample exceeds 60, optionally 150 μg / dL.

35. The radiopharmaceutical composition of any preceding claim for use in a method of treating a neoplasm, wherein the dose of the radiopharmaceutical composition is from 7 MBq / kg to 210 MBq / kg, optionally from 13 MBq / kg to 105 MBq / kg.

36. The radiopharmaceutical composition of any preceding claim for use in a method of treating a neoplasm, wherein the treatment is repeated 1 to 7 times per cycle.

37. The radiopharmaceutical composition of any preceding claim for use in a method of treating a neoplasm, wherein each cycle can be repeated between one and seven times.

38. The radiopharmaceutical composition of any preceding claim for use in a method of treating a neoplasm, wherein the frequency of administration comprises 1 to 3 administrations per week.

39. A radiopharmaceutical composition according to any one of the preceding claims for use in a method of treating a neoplasm, wherein for each treatment cycle, the dosage regimen is gradually increased from an initial treatment dose (X1) as follows: or as a fixed dose of a radiopharmaceutical composition.

40. A radiopharmaceutical composition according to any of the preceding claims for use in a method of treating a neoplasm, wherein for each treatment cycle the dosage regimen comprises the following doses for an adult patient: Dose 1 = 1,850 MBq, Dose 2 = 2,460 MBq, Dose 3 = 2,922 MBq, Dose 4 = 3,292 MBq, Dose 5 = 3,606 MBq, Dose 6 = 3,865 MBq, Dose 7 = 4,068 MBq, with a total activity equal to 22,063 MBq per cycle.

41. A radiopharmaceutical composition according to any of the preceding claims for use in a method of treating a neoplasm, wherein for each treatment cycle the dosage regimen comprises the following doses for an adult patient: Dose 1 = 4,810 MBq, Dose 2 = 4,810 MBq, Dose 3 = 4,810 MBq, Dose 4 = 4,810 MBq, Dose 5 = 4,810 MBq, Dose 6 = 4,810 MBq, Dose 7 = 4,810 MBq, wherein the total activity equals 33,670 MBq per cycle.

42. A radiopharmaceutical composition according to any of the preceding claims for use in a method of treating a neoplasm, wherein for each treatment cycle the dosage regimen comprises the following doses for pediatric patients: Dose 1 = 1,700 MBq, Dose 2 = 1,700 MBq, Dose 3 = 1,700 MBq, Dose 4 = 1,700 MBq, Dose 5 = 1,700 MBq, Dose 6 = 1,700 MBq, Dose 7 = 1,700 MBq, wherein the total activity administered is equal to 11,900 MBq x cycle.

43. A radiopharmaceutical composition according to any preceding claim for use in a method of treating a neoplasm, wherein the treatment is followed by a period of monitoring the patient's response to the treatment.

44. The radiopharmaceutical composition of any preceding claim, further comprising a counterion present in solution selected from the group consisting of chloride, acetate and citrate ions.

45. A radiopharmaceutical composition according to any one of the preceding claims comprising 5% 64 CuCl2, 2% acetate buffer solution and 10-93% 0.9% NaCl solution.

46. ​​A radiopharmaceutical composition according to any one of the preceding claims comprising 8% 64 Cu(OAc)2, 4% acetate buffer solution, 12-88% water for injection (WFI) and 1% antioxidant.

47. The radiopharmaceutical composition according to any of the preceding claims, having a pH suitable for direct injection, said pH having a value between 4 and 8.

48. A method for treating a tumor comprising administering a radiopharmaceutical composition comprising copper-64( 64 Cu ++ ), in combination with suitable excipients and / or diluents in saline solution, having a radioactivity concentration at calibration of between 50 and 3,500 MBq / mL, optionally equal to, below or above 925 MBq / mL.

49. A method of treatment according to claim 48, wherein the method is preceded by a stage of assessing whether the patient is suitable for treatment.

50. The method of treatment of claim 48, wherein the evaluating comprises performing PET / MRI or PET / CT on the patient to confirm copper-64 uptake by the neoplasm.

51. The method of treatment of claim 49, wherein the assessment is performed by a method including output from a computer.

52. A method of treatment according to claim 51, wherein the output of the computer does not require interpretation by a physician.

53. A method of treatment according to any one of claims 48 to 52, wherein the treatment is followed by a period of monitoring the patient's response to the treatment.

54. A radiopharmaceutical composition comprising as an active ingredient copper-64( 64 Cu ++ ), whose radioactivity concentration at the time of calibration is between 50 and 3,500 MBq / mL, optionally equal to, lower than or higher than 925 MBq / mL, for the preparation of a drug.

55. A radiopharmaceutical composition for use in the preparation of a medicament according to claim 54, wherein the medicament is for the treatment of a neoplasm.

56. A radiopharmaceutical composition for use in the preparation of a medicament according to claims 54-55, wherein the medicament is also used to assess or monitor cellular uptake of copper-64 using PET / MRI or PET / CT.

57. A radiopharmaceutical composition for use in the preparation of a medicament according to claim 56, wherein said assessing or monitoring is performed by a method comprising output from a computer.

58. A radiopharmaceutical composition for use in the preparation of a medicament according to claim 57, wherein the output of the computer does not require interpretation by a physician.

59. The radiopharmaceutical composition of claim 54, wherein the composition is used in a phase of monitoring a patient's response to treatment.